An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to- moderate persistent asthma
(2004) In Respiratory Medicine 98(11). p.1146-1154- Abstract
- Patients with mild asthma may benefit from increasing their inhaled corticosteroid dose, adding a tong-acting beta(2)-agonist, or both. This study assessed the cost-effectiveness of these options. Patients aged greater than or equal to12 years with mild-to-moderate persistent asthma (n = 1272) were randomised to twice-daily, double-blind treatment with budesonide 100 mug, budesonide 100 mug plus formoterol 4.5 mug, budesonide 200 mug, or budesonide 200 mug plus formoterol 4.5 mug for 12 months. Clinical variables included lung function, number of symptom-free days and number of severe exacerbations. Data on medication use, hospitalisation, visits to health professionals and time off work due to asthma were combined with Swedish unit cost... (More)
- Patients with mild asthma may benefit from increasing their inhaled corticosteroid dose, adding a tong-acting beta(2)-agonist, or both. This study assessed the cost-effectiveness of these options. Patients aged greater than or equal to12 years with mild-to-moderate persistent asthma (n = 1272) were randomised to twice-daily, double-blind treatment with budesonide 100 mug, budesonide 100 mug plus formoterol 4.5 mug, budesonide 200 mug, or budesonide 200 mug plus formoterol 4.5 mug for 12 months. Clinical variables included lung function, number of symptom-free days and number of severe exacerbations. Data on medication use, hospitalisation, visits to health professionals and time off work due to asthma were combined with Swedish unit cost data (1999) to estimate the mean annual cost per patient. Budesonide 200 mug plus formoterol 4.5 mug had the greatest efficacy and effectiveness. Budesonide 200 mug plus formoterol 4.5 mug was both more effective and less costly than budesonide 100 mug plus formoterol 4.5 mug, so a cost-effectiveness ratio was not calculated for this comparison. The cost-effectiveness ratio for budesonide 200 mug plus formoterol 4.5 mug compared with budesonide 200 mug alone was SEK 21 per symptom-free days gained. The combination of budesonide and formoterol in mild-to-moderate persistent asthma improved effectiveness at modest additional cost. (C) 2004 Elsevier Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/262274
- author
- Jonsson, B ; Berggren, Fredrik LU ; Svensson, K and O'Byrne, PM
- organization
- publishing date
- 2004
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- budesonide, formoterol, mild-to-moderate asthma, economic evaluation
- in
- Respiratory Medicine
- volume
- 98
- issue
- 11
- pages
- 1146 - 1154
- publisher
- Elsevier
- external identifiers
-
- wos:000224709700015
- pmid:15526817
- scopus:4844224532
- ISSN
- 1532-3064
- DOI
- 10.1016/j.rmed.2004.04.005
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Lund University Centre for Health Economics (LUCHE) (016630120), Division of Health Economics and Forensic Medicine (Closed 2012) (013040050)
- id
- 8ae6e8d6-be06-4df4-bc5e-5c2828d44e58 (old id 262274)
- date added to LUP
- 2016-04-01 15:48:30
- date last changed
- 2022-03-22 06:22:30
@article{8ae6e8d6-be06-4df4-bc5e-5c2828d44e58,
abstract = {{Patients with mild asthma may benefit from increasing their inhaled corticosteroid dose, adding a tong-acting beta(2)-agonist, or both. This study assessed the cost-effectiveness of these options. Patients aged greater than or equal to12 years with mild-to-moderate persistent asthma (n = 1272) were randomised to twice-daily, double-blind treatment with budesonide 100 mug, budesonide 100 mug plus formoterol 4.5 mug, budesonide 200 mug, or budesonide 200 mug plus formoterol 4.5 mug for 12 months. Clinical variables included lung function, number of symptom-free days and number of severe exacerbations. Data on medication use, hospitalisation, visits to health professionals and time off work due to asthma were combined with Swedish unit cost data (1999) to estimate the mean annual cost per patient. Budesonide 200 mug plus formoterol 4.5 mug had the greatest efficacy and effectiveness. Budesonide 200 mug plus formoterol 4.5 mug was both more effective and less costly than budesonide 100 mug plus formoterol 4.5 mug, so a cost-effectiveness ratio was not calculated for this comparison. The cost-effectiveness ratio for budesonide 200 mug plus formoterol 4.5 mug compared with budesonide 200 mug alone was SEK 21 per symptom-free days gained. The combination of budesonide and formoterol in mild-to-moderate persistent asthma improved effectiveness at modest additional cost. (C) 2004 Elsevier Ltd. All rights reserved.}},
author = {{Jonsson, B and Berggren, Fredrik and Svensson, K and O'Byrne, PM}},
issn = {{1532-3064}},
keywords = {{budesonide; formoterol; mild-to-moderate asthma; economic evaluation}},
language = {{eng}},
number = {{11}},
pages = {{1146--1154}},
publisher = {{Elsevier}},
series = {{Respiratory Medicine}},
title = {{An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to- moderate persistent asthma}},
url = {{http://dx.doi.org/10.1016/j.rmed.2004.04.005}},
doi = {{10.1016/j.rmed.2004.04.005}},
volume = {{98}},
year = {{2004}},
}